The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity
Matthias Oelze(University Medical Center of the Johannes Gutenberg University Mainz), Andreas Daiber(Johannes Gutenberg University Mainz)
Cited by 291
Related Papers
The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
|Redox Biology|2017|303